Poster Abstract Session:
250. Treatment of AMR Infections
Saturday, October 6, 2018: 12:30 PM-1:45 PM
Room: S Poster Hall

Tracks: Pediatric ID, Epidemiology and Infection Control, Adult ID

Multicenter Evaluation of Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections
Sarah Jorgensen, PharmD, BCPS, AAHIVP; Trang D. Trinh, PharmD, MPH; Evan J. Zasowski, PharmD, MPH; Abdalhamid M. Lagnf, MPH; Sahil Bhatia, B.S.; Samuel Simon, PharmD; Sandy Estrada, Pharm.D., BCPS (AQ-ID); Joshua Rosenberg, MD; Molly Steed, PharmD; Susan L Davis, PharmD; Michael J. Rybak, PharmD, MPH, PhD
Healthcare Resource Utilization for High-Risk Patients Treated with Dalbavancin in Physician Office Infusion Centers (POICs)
Quyen Luu, MD; Barry Statner, MD, FRCPC, FIDSA; Robin H. Dretler, MD, FIDSA; H. Barry Baker, MD, FACP; Brian S. Metzger, MD, MPH; Thomas C. Hardin, PharmD; Claudia P. Schroeder, PharmD, PhD; Lucinda J. Van Anglen, PharmD
Ceftolozane/tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Resistance
Vidmantas Petraitis, MD; Ruta Petraitiene, MD; Ethan Naing, MD; Thein Aung, MD; Wai Phyo Thi, MD; Povilas Kavaliauskas, BS; C. Andrew DeRyke, PharmD; Darren L Culshaw, PharmD; Luzelena Caro, PhD; Michael J. Satlin, MD, MS; Thomas J. Walsh, MD, PhD
Ceftolozane/tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections in Immunocompromised Patients: A Multi-Center Study.
Abdulrahman Elabor, MD; Esther Molnar, MD; Madeline King, Pharm D; Jason Gallagher, PharmD, FCCP, FIDSA, BCPS
  • project copy copy-converted.pdf (482.8 kB)
  • Multidrug-Resistant Gram-Negative Infections Treated with Ceftolozane-Tazobactam: Impact of Delayed Initiation
    Sarah Jorgensen, PharmD, BCPS, AAHIVP; Trang D. Trinh, PharmD, MPH; Evan J. Zasowski, PharmD, MPH; Abdalhamid M. Lagnf, MPH; Sahil Bhatia, B.S.; Samuel Simon, PharmD; Sandy Estrada, Pharm.D., BCPS (AQ-ID); Joshua Rosenberg, MD; Molly Steed, PharmD; Susan L Davis, PharmD; Michael J. Rybak, PharmD, MPH, PhD
    Ceftazidime-Avibactam in Combination with Fosfomycin: A Novel Therapeutic Strategy against Multidrug Resistant Pseudomonas aeruginosa
    Krisztina M. Papp-Wallace, PhD; Elise T. Zeiser, BS, MPH; Scott A. Becka, BS; Steven T. Park, MS; Marisa L. Winkler, MD/PhD; Kevin Nguyen, BS; Indresh Singh, MS; Granger Sutton, PhD; Derrick E. Fouts, PhD; Evelyn J. Ellis-Grosse, PhD; George L. Drusano, MD; David S. Perlin, PhD; Robert A. Bonomo, MD
    Efficacy of Lefamulin (LEF) Versus (vs) Moxifloxacin (MOX) Against Common Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Results from the Phase 3 Lefamulin Evaluation Against Pneumonia (LEAP 1) Study
    Thomas File, MD; Lisa Goldberg, MS; Susanne Paukner, PhD; Anita Das, PhD; Steven P. Gelone, PharmD; John Saviski, MS; Carolyn Sweeney, BS; Elyse Seltzer, MD; George H. Talbot, MD; Leanne B. Gasink, MD
  • IDWeek LEAP1 Micro_2386.pdf (509.7 kB)
  • Efficacy of Humanized Cefiderocol Exposures over 72 hours Against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model
    Sean Stainton, PharmD; Marguerite Monogue, PharmD; Masakatsu Tsuji, Ph.D; Yoshinori Yamano, Ph.D; Roger Echols, MD, FIDSA; David P. Nicolau, PharmD, FCCP, FIDSA
    Effect of Rezafungin on QT interval in Healthy Subjects
    Shawn Flanagan, PhD; Daniel B. Goodman, MD; Pallavi Rao, BSN, RN; Alena Jandourek, MD; Terry O'Reilly, MD, CPI; Taylor Sandison, MD, MPH
  • 2018 IDWeek_QT_FINAL.pdf (452.4 kB)
  • Avibactam Sensitizes NDM Klebsiella pneumoniae to Innate Immune Killing by Human Cathelicidin LL-37, Serum, Neutrophils and Platelets
    Erlinda Rose Ulloa, MD, MSc; Nicholas Dillon, PhD, MS; George Sakoulas, MD; Victor Nizet, MD
    Liposomal Vancomycin and Cefazolin Combinations for S. aureus Biofilms
    Razieh Kebriaei, PhD; Ketki Bhise, PhD candidate; Samaresh Sau, PhD; Seth Rice, BSc; Kyle Stamper, BSc; Arun Iyer, PhD; Michael J. Rybak, PharmD, MPH, PhD
    Fosfomycin Utilization and Outcomes in a Large VA Medical Center Over a Decade
    Natan Kraitman, M.D.; Jaela Fredenrich, PharmD; Brandon DeLucca, PharmD; John Toney, MD, FACP, FIDSA
  • ID Week_Fosfomycin Poster-1.pdf (352.0 kB)
  • Evaluation of Antifungal Treatment in a Neutropenic Mouse Model of Scedosporiosis
    Sondus Alkhazraji, PhD; Teclegiorgis Gebremariam, MS; Abdullah Alqarihi, MS; Clara Baldin, PhD; Nathan P. Wiederhold, PharmD; Therese Kitt, MD; Ashraf S. Ibrahim, PhD
    Different Clostridioides difficile Ribotypes among Patients with Colonization, Initial Clinical Disease and Recurrent Clinical Disease
    Kevin Khoury, MD; Eugene Yen, MD; Jennifer Grant, MD; Se Hyuk Park, MS; Talent Thaparee, MD; Donna Schora, MT(ASCP); Becky Smith, MD; Kamaljit Singh, MD; Sanchita Das, MD
    Mechanism-based-susceptibility testing (MBST) using disc diffusion assays (DDA) to Guide Treatment of Multidrug- and Extensively Drug Resistant Pseudomonas aeruginosa (MDR-XDR-Pa) in a Cystic Fibrosis (CF) Lung Transplant Recipient; are we ready for combination therapy vs. MDR-XDR-Pa?
    Lilian M. Abbo, MD; Mohamad Yasmin, MD; Steven H. Marshall, MS; Federico Perez, MD, MS; Mónica Corzo-Pedrosa, MD; Jose F. Camargo, MD; Jacques Simkins, MD; Laura Aragon, PharmD, BCPS-AQ ID; Shweta Anjan, MD; Michele I Morris, MD, FIDSA, FAST; Nicolas Brozzi, MD; Mathias Loebe, MD; Jesse Fulmer, MD; Neeraj Sinha, MD; Octavio Martinez, PhD; Armando Perez-Cardona, BS; Andrew Colin, MD; Christina Cloke, MD; Robert A. Bonomo, MD
    Fosfomycin Resistance among Carbapenem-Resistant Enterobacteriaceae Clinical Isolates in Connecticut, 2017
    Mary Snayd, MD; Vivian Leung, MD; Meghan Maloney, MPH; Amanda Durante, PhD, MSc; Bobbie Macierowski, MS; Diane Noel, MT; Anthony Muyombwe, PhD; Jafar Razeq, PhD; David Banach, MD, MPH, MS
    Comparing Predictive Performance of INCREMENT Scores on Mortality Among Patients with Carbapenem-Non-Susceptible (CNS) Klebsiella pneumoniae (Kp) and Enterobacter cloacae Complex (Ecc) Bloodstream Infections (BSI) in the Veterans Health Administration (VHA)
    Nadim G. El Chakhtoura, MD, MPH; Brigid Wilson, PhD; Belen Gutíerrez-Gutíerrez, MD, PhD; Federico Perez, MD, MS; Elie Saade, MD, MPH; Curtis J. Donskey, MD; Jesus Rodriguez-Bano, MD; Robert A. Bonomo, MD
    Utilization Practices of Ceftazidime-avibactam at Academic Medical Centers in the United States
    Jeffrey R. Strich, MD; Emily Ricotta, PhD, ScM; Yi Ling Lai, MPH; Samuel Hohmann, PhD; Sadia Hussain, MD; Chanu Rhee, MD, MPH; Michael Klompas, MD, MPH, FRCPC, FIDSA; Tara N. Palmore, M.D.; John H. Powers III, MD; John P. Dekker, M.D., Ph.D.; Jennifer Adjemian, PhD; Robert L. Danner, MD; Sameer S. Kadri, MD, MS
    Beta-Lactam Therapy for Potential AmpC-Producing Organisms: A Cohort Study and an Updated Systematic Review and Meta-analysis
    Matthew P. Cheng, MD; Robyn Lee, PhD; Alexandre P. Cheng, BSc; Samuel De L'Étoile-Morel, MD; Koray Demir, MDCM Candidate; Cedric Yansouni, MD; Patrick Harris, MBBS FRACP FRCPA; Emily Mcdonald, MDCM, MSc; Todd C. Lee, MD, MPH
    Activity of a Long-Acting Echinocandin, Rezafungin, Tested against Invasive Fungal Isolates Collected Worldwide
    Michael A. Pfaller, M.D.; Shawn A. Messer, MS-MT; Paul R. Rhomberg, BS; Beth A Schaefer, BS; Mariana Castanheira, PhD
  • IDWeek-2018-rezafungin.pdf (519.6 kB)
  • Risk factors for Antimicrobial Resistance in Invasive Pneumococcal disease (IPD) in Toronto, Canada, 2012-2017
    Thomas Fear, MD; Karen Green, MSc, RN; Agron Plevneshi, BSc; Jeff Li, BSc; Wallis Rudnick, MSc; Sarah Nayani, PhD; Allison McGeer, MD, MSc
  • thomas fear IPD AMR poster5.pdf (775.0 kB)
  • Daptomycin Pulmonary Eosinophilia: Review of Cases and New Hyperacute Syndromic Presentation
    Katelyn West, MS; Kimberly Mackay, Pharm D; Graeme N. Forrest, MBBS, FIDSA
    Comparison of Daptomycin Combination Therapy with Ceftaroline or Oxacillin Against Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates Causing Persistent Bacteremia
    Jeannette Bouchard, PharmD; Chelsea Jones, BA; Ellen Kline, MS; Louise-Marie Oleksiuk, PharmD; Ryan K. Shields, PharmD
    Telavancin (TLV) and Vancomycin (VAN) Activity and Impact on Mechanical Properties When Incorporated into Orthopedic Bone Cement
    Aaron Bishop, MS; Sunjung Kim, MS; Matthew Squire, MD; Heidi-Lynn Ploeg, PhD; Warren Rose, PharmD, MPH
  • IDWeek TLV poster FINAL.PDF (2.0 MB)
  • In vitro synergistic activity of sitafloxacin in combination with colistin against clinical isolates of multidrug resistant- Acinetobacter baumannii in Thailand
    Vipavee Rodjun, Rescident; Taniya Paiboonvong, MS; Jantana Houngsaitong, MS; Preecha Montakantikul, Assoc. Prof.
    "Real World" Treatment of Multi-drug Resistant (MDR) or Extensively-drug Resistant (XDR) P. aeruginosa Infections with Ceftolozane/Tazobactam (C/T) versus a Polymyxin or Aminoglycoside (Poly/AG) based regimen: A Multicenter Comparative Effectiveness Study
    Jason M. Pogue, PharmD, BCPS-AQ ID; Keith S. Kaye, MD, MPH; Michael Veve, PharmD; Anthony Gerlach, PharmD; Twisha S. Patel, PharmD, BCPS; Susan L Davis, PharmD; Eugene Chaung, MD; Amy Ray, MD, MPH; Laura Puzniak, PhD, MPH; Robert A. Bonomo, MD; Federico Perez, MD, MS
    Emerging Piperacillin/Tazobactam Resistance in Escherichia coli and Klebsiella sp..
    Mira Suseno, PharmD, BCPS-AQ ID; Sanchita Das, MD; Jeffery Semel, MD, FIDSA, FSHEA; Richard Thomson Jr., PhD
    Delayed Appropriate Antimicrobial Therapy Does Not Affect The Clinical Outcome of Patients With Acute Pyelonephritis by Extended-spectrum β-lactamase-producing Enterobacteriaceae
    Si-Ho Kim, MD; Suhyun Oh, MD; Sukbin Jang, MD; Seokjun Mun, MD; Kyungmin Huh, MD; Sun Young Cho, MD; Cheol-In Kang, MD; Doo Ryun Chung, MD PhD; Kyong Ran Peck, MD
    Drug-Induced Liver Injury (DILI) in a National Cohort of Hospitalized Patients treated with Aztreonam and Ceftazidime
    Elie Saade, MD, MPH; Brigid Wilson, PhD; Nadim G. El Chakhtoura, MD, MPH; Roberto Viau, MD; Federico Perez, MD, MS; Thomas Lodise, PharmD, PhD; Robert a. Bonomo, MD
    Clinical outcomes associated with various treatment options for infections caused by carbapenem-resistant Enterobacteriaceae
    Aiman Bandali, Pharm.D, AAHIVP; Caytlin Deering, DO; Tiffany Bias, PharmD, BCPS, AAHIVP; Elizabeth Gancher, MD
    Expanded Susceptibility and Resistance Mechanism Testing Among Carbapenem-Resistant Enterobacteriaceae in Connecticut, 2017
    Amanda Durante, PhD, MSc; Meghan Maloney, MPH; Vivian Leung, MD; Bobbie Macierowski, MS; Diane Noel, MT; Jafar Razeq, PhD; David Banach, MD, MPH, MS
    Our Experience With IV Fosfomycin
    Pratik Savaj, DNB; Kanishka Davda, DNB; Ayesha Sunavala, FNB; Rajeev Soman, MD, FIDSA
    The Role of Minocycline in the Treatment of Nosocomial Infections Caused by Multidrug, Extensively Drug and Pandrug Resistant Acinetobacter baumannii: A Systematic Review of Clinical Evidence.
    Paraskevi C. Fragkou, MD, MSc; Garyfallia Poulakou, MD, PhD; Myrto Blizou, MD; Andromachi Blizou, MD; Dimitrios K. Matthaiou, MD, MBA, PhD; Sotirios Tsiodras, MD, MSc, PhD, FIDSA
  • poster2413.jpg (3.5 MB)
  • Real World Evaluation of Patient Characteristics and Outcomes of Patients Treated with Ceftolozane/Tazobactam across 253 US hospitals
    Laura Puzniak, PhD, MPH; Rao Fu, PhD, MPH; Jake Gundrum, MS; Thomas P. Lodise Jr., PharmD, PhD
    Comparison of minocycline MIC's obtained by Etest to those obtained by broth microdilution in a bank of isolates of Acinetobacter baumannii collected in Southeastern Michigan
    Leo Parsons II, D.O.; Jason M. Pogue, PharmD, BCPS-AQ ID; Paul Lephart, Ph.D.; Dina Boikov, Lab Assistant; Keith Kaye, MD, MPH; Sorabh Dhar, MD
  • Mino poster 4sd.pdf (425.1 kB)
  • Management of Carbapenem-resistant Enterobacteriaceae Infections in a Long-term Acute Care Hospital
    Patience Dogho, MBBS; Nancy Osadiaye, Medical Student; Osamuyimen Igbinosa, MD
  • CRE LTACH Poster.pdf (2.1 MB)
  • Tedizolid is well-tolerated among patients receiving prolonged treatment courses
    Rachel V. Marini, PharmD; Lloyd Clarke, BScHons; Ryan K. Shields, PharmD
    Efficacy of Cefoxitin for the treatment of urinary tract infection (UTI) due to ESBL-producing E. coli and K. pneumoniae isolates
    Olivia Senard, MD; Frederique Bouchand, PharmD; Laurene Deconinck, MD; Morgan Matt, MD; Lesly Fellous, PharmD; Martin Rottman, MD, PhD; Christian Perronne, MD, PhD; Aurelien Dinh, MD; Benjamin Davido, MD, MS
  • IDWEEK - Poster FOX.pdf (375.6 kB)
  • Effectiveness and Safety of Ceftolozane/Tazobactam (TOL/TAZ) Use for Carbapenem-Resistant Pseudomonas Infections in Children
    Leah Molloy, Pharm D; Ibrahim Abdulhamid, MD; Ruma Srivastava, MD; Jocelyn Ang, MD
  • Zerbaxa poster IDweek 2018.pdf (199.4 kB)
  • Review of Antimicrobial Susceptibility Profile of Different Nocardia Species, a Tertiary Center Experience
    Ahmed Hamdi, MD; Omar Abu Saleh, MD; Madiha Fida, MD; Alexandra Bryson, PhD; Nancy L. Wengenack, PhD, FIDSA
    Clinical and Microbiologic Outcomes Among Patients with Monomicrobial Stenotrophomonas maltophilia Infections
    Kenneth Klinker, PharmD; Cara Nys, Doctor of Pharmacy Student; Veena Venugopalan, PharmD; Kartikeya Cherabuddi, MD
    Ceftaroline-Associated Neutropenia: Retrospective Study and Systematic Review of Incidence, Risk Factors, and Outcomes
    Eva Sullivan, PharmD; Hollis O'neal, M.D., M.Sc.; R. Brigg Turner, Pharm D; Nancy Crum-Cianflone, MD, MPH
    Impact of USCAST proposed breakpoint changes to aminoglycosides, cyclines, and levofloxacin on carbapenem-resistant Enterobacteriaceae at a U.S. tertiary referral academic medical center
    Brandon Kulengowski, PharmD, MS; Gretchen Ingling, PharmD Candidate; Kristen E. Wilhite, PharmD Candidate; David S. Burgess, PharmD, FCCP, FIDP
  • USCAST Poster.pdf (355.2 kB)
  • Appropriateness of Empiric Extended-Infusion Piperacillin/Tazobactam in the Intensive Care Unit
    Kendall Tucker, PharmD; Molly Benning, BS; Keenan Ryan, PharmD, PhC; Carla Walraven, PharmD, MS; Bernadette Jakeman, PharmD, PhC, BCPS, AAHIVP
  • UNM_Poster_IDweek K Tucker.pdf (463.8 kB)
  • Review of Linezolid (LZD) Use and Onset of Toxicity in 4 Belgian Hospital Centers: a Retrospective Study
    Helene Thirot, PharmD; Caroline Briquet, PharmD; Frédéric Frippiat, MD; Frederique Jacobs, MD; Xavier Holemans, MD; Paul Tulkens, MD; Anne Spinewine, Pharm, PhD; Francoise Van Bambeke, PharmD, PhD
    Use of Piperacillin/Tazobactam vs. Cefepime or Carbapenem for Infections due to Serratia, Citrobacter or Enterobacter
    James Go, PharmD; Katie L. Wallace, PharmD, BCPS; David S. Burgess, PharmD, FCCP, FIDP; Donna R. Burgess, RPh; Sarah Cotner, PharmD, BCPS; Vaneet Arora, MD, MPH, D(ABMM)
    Colistin usage, Do we need to worry about its toxicity among children with cancer?
    Reham Khedr, MD, PhD; Naglaa Ahmed, PharmB, MSc; Mervat Alenany, PhD; Hanan Elabhar, PhD; Hala Salem, PhD; Hanafy Hafez, MD, PhD
  • ID WEEK - Colistin.jpg (6.4 MB)
  • Ceftolozane/tazobactam (C/T) against multidrug-resistant Pseudomonas aeruginosa (MDR-Pa) infections: Clinical efficacy, and baseline and emergent resistance
    Ryan K. Shields, PharmD; Ghady Haidar, MD; Brian A. Potoski, PharmD; Yohei Doi, MD, PhD; Rachel V. Marini, PharmD; M. Hong Nguyen, MD; Cornelius J. Clancy, M.D.
    Outcomes of Minocycline Use on Gram-Negative Infections and Implications of MIC
    Jennifer Cheng, PharmD; Christine J. Kubin, PharmD BCPS (AQ-ID)
    Outcomes of Patients with Vancomycin-resistant Enterococcus Blood Stream Infections (BSI) Treated with Daptomycin
    Luis A Shimose, MD; Maria X Bueno Rios, MD; Vasilios Athans, PharmD, BCPS; Stephanie Bass, PharmD; Manshi Li, MS; Xiaofeng Wang, PhD; Joshua Otiso, MPH, MLS (ASCP); Abhijit Duggal, MD, MPH, MSc; Sandra S. Richter, MD; Christopher Kovacs, MD
    Outcomes in ESBL Bacteremia Empirically Treated with Piperacillin/tazobactam or Carbapenems
    Reeba John, PharmD; Peter Colley, Pharm.D., BCPS; Hoa Nguyen, MD, MS, PhD; Mezgebe Berhe, MD, MPH
  • IDWeek Poster_ESBL.pdf (190.1 kB)
  • Incidence of Daptomycin Toxicity Among Patients with Vancomycin-resistant Enterococcus Blood Stream Infections
    Maria X Bueno Rios, MD; Luis A Shimose, MD; Vasilios Athans, PharmD, BCPS; Stephanie Bass, PharmD; Joshua Otiso, MPH, MLS (ASCP); Manshi Li, MS; Xiaofeng Wang, PhD; Abhijit Duggal, MD, MPH, MSc; Sandra S. Richter, MD; Christopher Kovacs, MD
    Efficacy and Tolerability of Linezolid for Treatment of Infectious Spondylitis
    Jongtak Jung, M.D; Eunyoung Lee, M.D.; Kyoung-Ho Song, M.D., Ph.D.; Pyeong Gyun Choe, M.D.; Nam Joong Kim, M.D., Ph.D.; Eu Suk Kim, M.D., Ph.D.; Ji Hwan Bang, M.D.; Sang Won Park, M.D., Ph.D.; Hong Bin Kim, M.D., Ph.D.; Wan Beom Park, M.D., Ph.D; Myoung-Don Oh, M.D., Ph.D.
  • poster_linezolid_IDweek.pdf (717.3 kB)
  • Clinical spectrum and outcomes of Colistin-resistant Carbapenem resistant Enterobacteriaceae
    Sara Ahmed, MBBS, FCPS Medicine; Syed Faisal Mahmood, MBBS, DABIM, DABIM (ID); Fatima Sharif, MBBS; Mariam Aijaz, MBBS; Safia Awan, MSc Statistics; Bushra Jamil, MBBS, FRCP, FACP
  • Poster IDWEEK 2018 CoRCRE 2.pdf (196.1 kB)
  • Ertapenem and faropenem for the treatment of drug resistant tuberculosis
    Giovanni Satta, MBBS MSc MBA FRCPath; Ximena Gonzalo, MBBS FRCPath; Julio Ortiz Canseco, PhD; Emmanuel Wey, MBBS MSc MRCPCH FRCPath; Francis Drobniewski, Professor; Timothy D McHugh, Professor
  • Poster2447.pdf (290.2 kB)
  • Validation of In vitro Activity of Aminoglycosides Against Recently Isolated Helicobacter pylori for Commercialization of Gentamicin-intercalated Smectite Hybrid as A New Therapeutic Agent
    Kyoung Hwa Lee, MD; Soon Young Park, MS; Seul Gi Yoo, MD; Da Eun Kwon, MD; Su Jin Jeong, MD/PhD; Da Hyun Jung, MD; Jie-Hyun Kim, MD/PhD; Seok Hoon Jeong, MD/PhD; Il-Mo Kang, MS; Young Goo Song, MD, PhD
    Antibiotic Treatment for Carbapenem-Resistant Enterobacteriaceae (CRE) and Outcomes in Veterans with Spinal Cord Injury/Disorder (SCI/D)
    Erica K. Little, PharmD; Ursula C. Patel, PharmD, BCPS, AAHIVP; Katie J. Suda, PharmD, M.S.; Margaret Fitzpatrick, MD, M.S.; Charlesnika T. Evans, PhD, MPH
    Treatment and Outcomes of Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Bloodstream Infections
    Hind Hadid, MD; Ana Cecilia Bardossy, MD; Helina Misikir, MPH; Mary Beth Perri, MT; Marcus Zervos, MD; Erica Herc, MD
    Repeated exposures to Minocycline/Rifampin and + Chlorhexidine combination used to coat catheters fails to induce antimicrobial resistance
    Nylev Vargas-Cruz, BS; Ruth Reitzel, PhD; Joel Rosenblatt, PhD; Ray Y. Hachem, MD; Anne-Marie Chaftari, MD; Rita Wilson Dib, MD; Issam Raad, MD

    CME Credits: Maximum of 0.00 hours of AMA PRA Category 1 Credit™

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.